Guangdong Taienkang Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Guangdong Taienkang Pharmaceutical has been growing earnings at an average annual rate of 12.4%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 7.4% per year. Guangdong Taienkang Pharmaceutical's return on equity is 6.6%, and it has net margins of 17.9%.
Belangrijke informatie
12.4%
Groei van de winst
2.9%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | 7.4% |
| Rendement op eigen vermogen | 6.6% |
| Nettomarge | 17.9% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Weak Statutory Earnings May Not Tell The Whole Story For Guangdong Taienkang Pharmaceutical (SZSE:301263)
Sep 03
Guangdong Taienkang Pharmaceutical Co., Ltd.'s (SZSE:301263) P/E Still Appears To Be Reasonable
Aug 23Here's Why Guangdong Taienkang Pharmaceutical (SZSE:301263) Can Manage Its Debt Responsibly
Jul 22Guangdong Taienkang Pharmaceutical (SZSE:301263) Is Paying Out Less In Dividends Than Last Year
May 22Guangdong Taienkang Pharmaceutical (SZSE:301263) Seems To Use Debt Quite Sensibly
Feb 26Opbrengsten en kosten
Hoe Guangdong Taienkang Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 752 | 135 | 202 | 75 |
| 30 Jun 24 | 751 | 137 | 205 | 71 |
| 31 Mar 24 | 756 | 154 | 206 | 64 |
| 31 Dec 23 | 761 | 160 | 206 | 63 |
| 30 Sep 23 | 791 | 189 | 212 | 64 |
| 30 Jun 23 | 814 | 206 | 209 | 57 |
| 31 Mar 23 | 794 | 173 | 224 | 50 |
| 01 Jan 23 | 783 | 175 | 215 | 40 |
| 30 Sep 22 | 759 | 168 | 194 | 29 |
| 30 Jun 22 | 712 | 140 | 190 | 25 |
| 31 Mar 22 | 697 | 157 | 164 | 25 |
| 01 Jan 22 | 654 | 120 | 166 | 26 |
| 30 Sep 21 | 661 | 124 | 177 | 31 |
| 30 Jun 21 | 668 | 127 | 174 | 32 |
| 31 Mar 21 | 670 | 133 | 165 | 32 |
| 31 Dec 20 | 709 | 161 | 157 | 31 |
| 30 Sep 20 | 662 | 138 | 148 | 33 |
| 30 Jun 20 | 612 | 119 | 133 | 30 |
| 31 Mar 20 | 565 | 87 | 130 | 27 |
| 31 Dec 19 | 496 | 55 | 117 | 24 |
| 30 Sep 19 | 496 | 56 | 106 | 19 |
| 30 Jun 19 | 512 | 69 | 105 | 20 |
| 31 Mar 19 | 523 | 76 | 99 | 20 |
| 31 Dec 18 | 514 | 74 | 100 | 20 |
| 30 Sep 18 | 486 | 71 | 98 | 20 |
| 30 Jun 18 | 480 | 67 | 97 | 20 |
| 31 Mar 18 | 457 | 58 | 89 | 28 |
| 31 Dec 17 | 450 | 55 | 89 | 24 |
| 30 Sep 17 | 430 | 43 | 87 | 19 |
| 30 Jun 17 | 408 | 35 | 86 | 14 |
| 31 Mar 17 | 378 | 31 | 90 | 0 |
| 31 Dec 16 | 367 | 28 | 90 | 0 |
| 30 Sep 16 | 382 | 38 | 90 | 0 |
| 30 Jun 16 | 398 | 49 | 90 | 0 |
| 31 Mar 16 | 384 | 45 | 82 | 0 |
| 31 Dec 15 | 370 | 42 | 75 | 0 |
| 30 Sep 15 | 337 | 36 | 65 | 0 |
| 30 Jun 15 | 304 | 29 | 56 | 0 |
| 31 Mar 15 | 305 | 35 | 55 | 0 |
| 31 Dec 14 | 304 | 40 | 52 | 0 |
| 31 Dec 13 | 280 | 48 | 44 | 0 |
Kwaliteitswinsten: 301263 has a high level of non-cash earnings.
Groeiende winstmarge: 301263's current net profit margins (17.9%) are lower than last year (23.9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 301263's earnings have grown by 12.4% per year over the past 5 years.
Versnelling van de groei: 301263's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 301263 had negative earnings growth (-28.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rendement op eigen vermogen
Hoge ROE: 301263's Return on Equity (6.6%) is considered low.